Tarek M.A. Abdel-Fatah
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
Abdel-Fatah, Tarek M.A.; Ali, Reem; Sadiq, Maaz; Moseley, Paul M.; Mesquita, Katia A.; Ball, Graham; Green, Andrew R.; Rakha, Emad A.; Chan, Stephen Y.T.; Madhusudan, Srinivasan
Authors
Reem Ali
Maaz Sadiq
Paul M. Moseley
Katia A. Mesquita
Graham Ball
Dr Andy Green ANDREW.GREEN@NOTTINGHAM.AC.UK
ASSOCIATE PROFESSOR
Emad A. Rakha
Stephen Y.T. Chan
Professor SRINIVASAN MADHUSUDAN srinivasan.madhusudan@nottingham.ac.uk
PROFESSOR OF MEDICAL ONCOLOGY
Abstract
Genomic instability could be a beneficial predictor for anthracycline or taxane chemotherapy. We interrogated 188 DNA repair genes in the METABRIC cohort (n = 1980) to identify genes that influence overall survival (OS). We then evaluated the clinicopathological significance of ERCC1 in early stage breast cancer (BC) (mRNA expression (n = 4640) and protein level, n = 1650 (test set), and n = 252 (validation)) and in locally advanced BC (LABC) (mRNA expression, test set (n = 2340) and validation (TOP clinical trial cohort, n = 120); and protein level (n = 120)). In the multivariate model, ERCC1 was independently associated with OS in the METABRIC cohort. In ER+ tumours, low ERCC1 transcript or protein level was associated with increased distant relapse risk (DRR). In ER−tumours, low ERCC1 transcript or protein level was linked to decreased DRR, especially in patients who received anthracycline chemotherapy. In LABC patients who received neoadjuvant anthracycline, low ERCC1 transcript was associated with higher pCR (pathological complete response) and decreased DRR. However, in patients with ER−tumours who received additional neoadjuvant taxane, high ERCC1 transcript was associated with a higher pCR and decreased DRR. High ERCC1 transcript was also linked to decreased DRR in ER+ LABC that received additional neoadjuvant taxane. ERCC1 based stratification is an attractive strategy for breast cancers.
Citation
Abdel-Fatah, T. M., Ali, R., Sadiq, M., Moseley, P. M., Mesquita, K. A., Ball, G., Green, A. R., Rakha, E. A., Chan, S. Y., & Madhusudan, S. (2019). ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers. Cancers, 11(8), Article 1149. https://doi.org/10.3390/cancers11081149
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 8, 2019 |
Online Publication Date | Aug 10, 2019 |
Publication Date | Aug 10, 2019 |
Deposit Date | Aug 9, 2019 |
Publicly Available Date | Aug 9, 2019 |
Journal | Cancers |
Electronic ISSN | 2072-6694 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 11 |
Issue | 8 |
Article Number | 1149 |
DOI | https://doi.org/10.3390/cancers11081149 |
Keywords | Cancer Research; Oncology |
Public URL | https://nottingham-repository.worktribe.com/output/2410659 |
Publisher URL | https://www.mdpi.com/2072-6694/11/8/1149 |
Contract Date | Aug 9, 2019 |
Files
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
(1 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
The characteristics and prognostic significance of histone H1 expression in breast cancer
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search